STAT5A and breast carcinoma: In contrast, our initial study of a breast cancer progression material by using a pan-Stat5a/b antibody indicated that malignant breast tumors generally remained positive for expression of Stat5 protein across the progression series, although quantification was not attempted, and the antibody used did not discern between Stat5a and Stat5b [29].